Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, today announced that it will present data
from the MoveDMD® trial of edasalonexent (CAT-1004) at the
New Directions in Biology and Disease of Skeletal Muscle Conference, the
2018 Parent Project Muscular Dystrophy (PPMD) Annual Connect Conference
and the 15th International Congress on Neuromuscular Diseases.
About Edasalonexent (CAT-1004)Edasalonexent (CAT-1004) is
an investigational oral small molecule that is being developed as a
potential disease-modifying therapy for all patients affected by DMD,
regardless of their underlying mutation. Edasalonexent inhibits NF-kB, a
protein that is activated in DMD and drives inflammation, fibrosis and
muscle degeneration and suppresses muscle regeneration. Edasalonexent
continues to be dosed in an open-label extension of the MoveDMD Phase 2
clinical trial, and Catabasis is preparing for a single global Phase 3
trial to evaluate the efficacy and safety of edasalonexent for
registration purposes, dependent on raising capital. The FDA has granted
orphan drug, fast track and rare pediatric disease designations and the
European Commission has granted orphan medicinal product designation to
edasalonexent for the treatment of DMD. For a summary of clinical
results reported to-date, please visit www.catabasis.com.
About CatabasisAt Catabasis Pharmaceuticals, our mission is
to bring hope and life-changing therapies to patients and their
families. Our lead program is edasalonexent, an NF-kB inhibitor in
development for the treatment of Duchenne muscular dystrophy.
Edasalonexent was designed using our SMART (Safely Metabolized And
Rationally Targeted) Linker drug discovery platform that enables us to
engineer molecules that simultaneously modulate multiple targets in a
disease. For more information on edasalonexent or our drug discovery
platform, please visit www.catabasis.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180618005026/en/